According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.